However, there was no significant difference in DMFS in BC patients either with HER-2 positive (HR = 0.73, p = 0.32) tumors or Basal-like (HR = 0.6, p = 0.051) between high and low FoxM1 mRNA expression (Figure 4G–4H). The gene discussed is ERBB2; the disease is breast cancer.